NIAID

The National Institute of Allergy and Infectious Diseases (NIAID) has released its 2027 Division of Microbiology and Infectious Diseases (DMID) Omnibus Broad Agency Announcement (BAA) to advance medical interventions for infectious diseases. The solicitation covers three research areas: needle-free vaccines, therapeutic candidates, and in vitro diagnostic platforms. Full proposals for all three areas must be

NIAID_Presolicitation_Notice_Rad_Nuc MCMs Overview of Solicitation The National Institute of Allergy and Infectious Diseases (NIAID), under the National Institutes of Health (NIH), has released a pre-solicitation notice for the development of Radiation/Nuclear Medical Countermeasures (MCMs) and Biodosimetry Devices. This Broad Agency Announcement (BAA 75N93024R00020) is an invitation for innovators in the critical field of radiation emergency

HHS-NIH-NIAID-BAA2025-1 The U.S. Department of Health and Human Services (HHS), through the National Institutes of Health (NIH) and the National Institute of Allergy and Infectious Diseases (NIAID), has released the Broad Agency Announcement (BAA) HHS-NIH-NIAID-BAA2025-1. This announcement presents an exciting opportunity for researchers, organizations, and industry leaders to contribute to critical biomedical and biodefense initiatives.

Pre-solicitation_Notice_-_BAA2025-1_Final Overview of Solicitation The upcoming 2026 Omnibus Broad Agency Announcement (BAA) is from the National Institute of Allergy and Infectious Diseases (NIAID), a division of the National Institutes of Health (NIH) under the Department of Health and Human Services (DHHS). NIAID’s mission centers on understanding, treating, and preventing infectious, immunologic, and allergic diseases. Through